LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 1195

Suchoptionen

  1. Artikel ; Online: Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.

    Scheen, André J

    Expert opinion on drug safety

    2024  , Seite(n) 1–14

    Abstract: Introduction: Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a key objective in T2DM.: Areas covered: Glucagon-like peptide-1 receptor ... ...

    Abstract Introduction: Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a key objective in T2DM.
    Areas covered: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven their efficacy in reducing major cardiovascular events in high-risk patients with T2DM in placebo-controlled trials, a finding confirmed in observational studies compared with other glucose-lowering agents. Overall, GLP-1RAs have a good safety profile associated with a favorable benefit/risk ratio for the management of T2DM, even if their cost-effectiveness might be questionable. International guidelines recommend GLP-1RAs as preferred glucose-lowering agents in patients with ASCVD and as a valuable alternative in overweight/obese patients with T2DM. However, real-life studies worldwide revealed that only a minority of patients receive a GLP-1RA, despite a positive trend for increased prescriptions in recent years. Surprisingly, however, fewer patients with established ASCVD are treated with these cardioprotective antihyperglycemic agents versus patients without ASCVD.
    Expert opinion: The reasons for GLP-1RA underuse in clinical practice are multiple. Multifaceted and coordinated interventions targeting all actors of the health-care system must be implemented to stimulate the adoption of GLP-1RAs as part of routine cardiovascular care among patients with T2DM, especially in those with ASCVD.
    Sprache Englisch
    Erscheinungsdatum 2024-05-13
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2088728-0
    ISSN 1744-764X ; 1474-0338
    ISSN (online) 1744-764X
    ISSN 1474-0338
    DOI 10.1080/14740338.2024.2354885
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel: [Titelangabe fehlt]

    Scheen, A J

    Revue medicale de Liege

    2023  Band 78, Heft 1, Seite(n) 1–3

    Titelübersetzung Éditorial. Le système des soins de santé ébranlé par les crises.
    Mesh-Begriff(e) Humans ; Delivery of Health Care
    Sprache Französisch
    Erscheinungsdatum 2023-01-12
    Erscheinungsland Belgium
    Dokumenttyp Editorial
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: Does race/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes?-a comparison between Asian versus White patients.

    Scheen, André J

    Annals of translational medicine

    2023  Band 10, Heft 24, Seite(n) 1418

    Sprache Englisch
    Erscheinungsdatum 2023-01-20
    Erscheinungsland China
    Dokumenttyp Editorial ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm-2022-54
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation.

    Scheen, André J

    The Lancet regional health. Europe

    2023  Band 29, Seite(n) 100627

    Sprache Englisch
    Erscheinungsdatum 2023-03-30
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2666-7762
    ISSN (online) 2666-7762
    DOI 10.1016/j.lanepe.2023.100627
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: [Titelangabe fehlt]

    Scheen, André J

    Revue medicale suisse

    2023  Band 19, Heft 838, Seite(n) 1483–1484

    Titelübersetzung Personnaliser l’approche du diabète de type 2 : chirurgie métabolique et/ou pharmacothérapie.
    Mesh-Begriff(e) Humans ; Diabetes Mellitus, Type 2 ; Bariatric Surgery
    Sprache Französisch
    Erscheinungsdatum 2023-08-23
    Erscheinungsland Switzerland
    Dokumenttyp Editorial
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2023.19.838.1483
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents.

    Scheen, André J

    The lancet. Diabetes & endocrinology

    2023  Band 11, Heft 9, Seite(n) 626–627

    Mesh-Begriff(e) Humans ; Glucose ; Hypoglycemic Agents/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Cardiovascular System ; Cardiovascular Diseases/prevention & control
    Chemische Substanzen Glucose (IY9XDZ35W2) ; Hypoglycemic Agents
    Sprache Englisch
    Erscheinungsdatum 2023-07-24
    Erscheinungsland England
    Dokumenttyp Journal Article ; Comment
    ISSN 2213-8595
    ISSN (online) 2213-8595
    DOI 10.1016/S2213-8587(23)00161-4
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel: Effets des médicaments antidiabétiques sur la stéatopathie métabolique (MAFLD).

    Scheen, André J

    Revue medicale suisse

    2023  Band 19, Heft 838, Seite(n) 1498–1502

    Abstract: Metabolic-Associated Fatty Liver Disease (MAFLD) is a prevalent metabolic complication among patients with obesity and type 2 diabetes, associated with bad prognosis. Classical antidiabetics have little effects on this complication, except pioglitazone ... ...

    Titelübersetzung Effects of antidiabetic medications on metabolic-associated fatty liver disease.
    Abstract Metabolic-Associated Fatty Liver Disease (MAFLD) is a prevalent metabolic complication among patients with obesity and type 2 diabetes, associated with bad prognosis. Classical antidiabetics have little effects on this complication, except pioglitazone that exerts a positive impact but with uncertain safety. Gliptins are almost neutral, whereas glucagon-like peptide-1 receptor agonists showed benefits, the most potent ones being those associated with a greater weight loss such as liraglutide or semaglutide. Gliflozins also reduce hepatic fat content and liver enzymes used as biomarkers of steatosis. However, histological data remain scarce, especially those focusing on inflammation and fibrosis, and direct comparative data between available therapies are still lacking.
    Mesh-Begriff(e) Humans ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/adverse effects ; Non-alcoholic Fatty Liver Disease/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors ; Liraglutide/therapeutic use
    Chemische Substanzen Hypoglycemic Agents ; Dipeptidyl-Peptidase IV Inhibitors ; Liraglutide (839I73S42A)
    Sprache Französisch
    Erscheinungsdatum 2023-08-23
    Erscheinungsland Switzerland
    Dokumenttyp English Abstract ; Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2023.19.838.1498
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel: Gestion des médicaments antidiabétiques dans le décours d’une chirurgie bariatrique/métabolique.

    Scheen, André J

    Revue medicale suisse

    2023  Band 19, Heft 838, Seite(n) 1492–1495

    Abstract: The management of type 2 diabetes (T2D) after a gastric bypass or a sleeve gastrectomy requires some cautions depending on the timing after the surgical procedure and the patient evolution. Even before the intervention, gliflozins should be interrupted ... ...

    Titelübersetzung Use of antidiabetic medications in the course of bariatric/metabolic surgery.
    Abstract The management of type 2 diabetes (T2D) after a gastric bypass or a sleeve gastrectomy requires some cautions depending on the timing after the surgical procedure and the patient evolution. Even before the intervention, gliflozins should be interrupted to avoid euglycemic diabetic ketoacidosis while sulphonylureas should be stopped and insulin doses should be reduced (with caution) to limit the risk of hypoglycemia. If a remission of T2D occurs, the maintenance of metformin or of a glucagon-like peptide-1 receptor agonist should be considered with the main objective to prolong the remission. Finally, if T2D remains or if a relapse occurs, the management of hyperglycemia should a priori follow the same rules as those used for patients with T2D who are not treated with bariatric/metabolic surgery.
    Mesh-Begriff(e) Humans ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/therapeutic use ; Bariatric Surgery/adverse effects ; Metformin ; Sulfonylurea Compounds
    Chemische Substanzen Hypoglycemic Agents ; Metformin (9100L32L2N) ; Sulfonylurea Compounds
    Sprache Französisch
    Erscheinungsdatum 2023-08-23
    Erscheinungsland Switzerland
    Dokumenttyp English Abstract ; Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2023.19.838.1492
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

    Scheen, André J

    Expert review of clinical pharmacology

    2023  Band 16, Heft 11, Seite(n) 1053–1062

    Abstract: Introduction: Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical practice.: Areas covered: Both ... ...

    Abstract Introduction: Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical practice.
    Areas covered: Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven their efficacy in reducing major cardiovascular events in high-risk patients with T2DM and SGLT2is in reducing hospitalization for HF in placebo-controlled randomized trials. However, real-life studies worldwide revealed that only a minority of patients with T2DM receive either a GLP-1RA or an SGLT2i and surprisingly even less patients with established ASCVD or HF are treated with these cardioprotective antihyperglycemic agents.
    Expert opinion: Bridging the gap between evidence-based cardiovascular protection with GLP-1RAs and SGLT2is and their underuse in daily clinical practice in patients with T2DM at high risk is crucial from a public health viewpoint. However, the task appears hazardous and the goal not attained considering the current failure. Education of specialists/primary care physicians and patients is critical. Multifaceted and coordinated interventions involving all actors (physicians, patients and broadly health-care system) must be implemented to stimulate the adoption of these cardioprotective antihyperglycemic medications as part of routine cardiovascular care among patients with T2DM.
    Mesh-Begriff(e) Humans ; Hypoglycemic Agents/adverse effects ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Cardiotonic Agents/pharmacology ; Heart Failure/drug therapy ; Atherosclerosis/complications ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/complications ; Glucagon-Like Peptide-1 Receptor/agonists
    Chemische Substanzen Hypoglycemic Agents ; Cardiotonic Agents ; Glucagon-Like Peptide-1 Receptor
    Sprache Englisch
    Erscheinungsdatum 2023-11-22
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 1751-2441
    ISSN (online) 1751-2441
    DOI 10.1080/17512433.2023.2279193
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review.

    Scheen, André J

    Expert review of endocrinology & metabolism

    2023  Band 18, Heft 4, Seite(n) 271–282

    Abstract: Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of their glucose-lowering potency.: Areas covered: The ... ...

    Abstract Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of their glucose-lowering potency.
    Areas covered: The antihyperglycaemic potency of SGLT2is was compared with that of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, especially when added to metformin monotherapy. Main results of cardiovascular/renal outcome trials with SGLT2is were summarized in different populations: patients with type 2 diabetes mellitus (T2DM) with or without established cardiovascular disease, patients (with or without T2DM) with heart failure (with reduced or preserved left ventricular ejection fraction) and in patients (with or without T2DM) with chronic kidney disease (CKD, including stage 4). Original papers and meta-analyses of these different trials have consistently reported a reduction in hospitalization for heart failure (alone or combined with cardiovascular mortality) and a reduced progression of CKD, with an overall good safety profile.
    Expert opinion: Global use of SGLT2is has increased over time but remains suboptimal despite clinically relevant cardiovascular and renal protection, particularly in patients most likely to benefit. SGLT2is has proven both positive benefit-risk balance and cost-effectiveness in at risk patients. New prospects are expected in other complications, i.e. metabolic-associated fatty liver disease and neurodegenerative disorders.
    Mesh-Begriff(e) Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Stroke Volume ; Ventricular Function, Left ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Heart Failure/drug therapy ; Glucose
    Chemische Substanzen Sodium-Glucose Transporter 2 Inhibitors ; Glucose (IY9XDZ35W2)
    Sprache Englisch
    Erscheinungsdatum 2023-05-08
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ISSN 1744-8417
    ISSN (online) 1744-8417
    DOI 10.1080/17446651.2023.2210673
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang